Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels

被引:26
作者
Otto, C
Otto, B
Göke, B
Pfeiffer, AFH
Lehrke, M
Vogeser, M
Spranger, J
Parhofer, KG
机构
[1] Univ Hosp Munich, Dept Med 2, D-81377 Munich, Germany
[2] Univ Hosp Munich, Dept Med, D-81377 Munich, Germany
[3] Univ Hosp Munich, Inst Clin Chem, D-81377 Munich, Germany
[4] German Inst Human Nutr, Dept Clin Nutr, Bergholz Rehbrucke, Germany
[5] Univ Med Berlin, Dept Endocrinol Diabet & Nutr, Charite, Berlin, Germany
[6] Univ Penn, Sch Med, Dept Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA
关键词
glitazone; PPAR; insulin sensitizer; insulin resistance; Type; 2; diabetes;
D O I
10.1007/BF03345545
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Glitazones increase the secretion of the adipocyte-clerived hormone adiponectin. Furthermore, the gastric signal peptide ghrelin is known to suppress adiponectin expression in adipocyte cell culture models. It is not known whether the increase in adiponectin during glitazone therapy is due to a suppression of ghrelin levels, a decrease of resistin concentrations or an amelioration of glucose control. In 10 patients (age 71 +/- 9 yr, body mass index 29.9 +/- 3.6 kg/m(2), HbA(1c) 6.9 +/- 0.5%) with Type 2 diabetes, who had already been treated with sulfonylureas, we additionally initiated a pioglitazone therapy (30 mg/day) for 12 weeks. To investigate the pioglitazone effect independently of blood glucose, glycosylated hemoglobin (HbA(1c)) was kept unchanged by reducing the daily dose of sulfonylurea if necessary. Ghrelin concentration [radioimmunoassay (RIA), Phoenix Pharmaceuticals, Mountain View, CA, USA], adiponectin levels [enzyme-linked immunosorbent assay (ELISA), Biovenclor, Heidelberg, Germany] as well as resistin concentrations (ELISA, Linco Research, St. Charles, MO, USA) were measured before and after pioglitazone. Glucose control remained unchanged within the 12-week pioglitazone therapy (HbA(1c) 6.9 +/- 0.5% before vs 6.8 +/- 0.6% after pioglitazone) while body weight increased from 86.6 +/- 9.2 to 88.0 +/- 9.4 kg (p < 0.05), and insulin concentration decreased from 19.6 +/- 5.7 to 10.1 +/- 11.6 mu U/ml (p < 0.05). Adiponectin concentration increased in all patients from 7.70 +/- 2.47 to 23.33 +/- 8.28 pg/ml (p < 0.01), while resistin concentrations tended to decrease (by 15%; p=0.059). However, ghrelin remained unchanged during therapy. No correlations were observed either between ghrelin, resistin, insulin and adiponectin, or between body weight and hormone plasma levels. The increase in adiponectin levels during pioglitazone therapy seems to be at least partly independent of blood glucose and insulin concentration as well as of ghrelin levels, and it was not associated with a decrease in resistin concentrations.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 28 条
[1]
Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay [J].
Akamizu, T ;
Shinomiya, T ;
Irako, T ;
Fukunaga, M ;
Nakai, Y ;
Nakai, Y ;
Kangawa, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) :6-9
[2]
Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients [J].
Bajaj, M ;
Suraamornkul, S ;
Hardies, LJ ;
Pratipanawatr, T ;
DeFronzo, RA .
INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (06) :783-789
[3]
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].
Berg, AH ;
Combs, TP ;
Du, XL ;
Brownlee, M ;
Scherer, PE .
NATURE MEDICINE, 2001, 7 (08) :947-953
[4]
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[5]
Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes [J].
Fasshauer, M ;
Klein, J ;
Neumann, S ;
Eszlinger, M ;
Paschke, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (03) :1084-1089
[6]
Sulfonylurea agents exhibit peroxisome proliferator-activated receptor γ agonistic activity [J].
Fukuen, S ;
Iwaki, M ;
Yasui, A ;
Makishima, M ;
Matsuda, M ;
Shimomura, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (25) :23653-23659
[7]
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors [J].
Iwaki, M ;
Matsuda, M ;
Maeda, N ;
Funahashi, T ;
Matsuzawa, Y ;
Makishima, M ;
Shimomura, I .
DIABETES, 2003, 52 (07) :1655-1663
[8]
Association of adiponectin mutation with type 2 diabetes - A candidate gene for the insulin resistance syndrome [J].
Kondo, H ;
Shimomura, I ;
Matsukawa, Y ;
Kumada, M ;
Takahashi, M ;
Matsuda, M ;
Ouchi, N ;
Kihara, S ;
Kawamoto, T ;
Sumitsuji, S ;
Funahashi, T ;
Matsuzawa, Y .
DIABETES, 2002, 51 (07) :2325-2328
[9]
PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein [J].
Maeda, N ;
Takahashi, M ;
Funahashi, T ;
Kihara, S ;
Nishizawa, H ;
Kishida, K ;
Nagaretani, H ;
Matsuda, M ;
Komuro, R ;
Ouchi, N ;
Kuriyama, H ;
Hotta, K ;
Nakamura, T ;
Shimomura, I ;
Matsuzawa, Y .
DIABETES, 2001, 50 (09) :2094-2099
[10]
Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease [J].
Marx, N ;
Froehlich, J ;
Siam, L ;
Ittner, J ;
Wierse, G ;
Schmidt, A ;
Scharnagl, H ;
Hombach, V ;
Koenig, W .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :283-288